Artelo (ARTL) FY 2025 net loss totals USD 12.9 million

Reuters02-24

Artelo (ARTL) FY 2025 net loss totals USD 12.9 million

Artelo Biosciences Inc. reported a FY 2025 net loss of USD 12.9 million, or USD 12.52 per basic and diluted share, alongside R&D expenses of USD 5.4 million and G&A expenses of USD 6.0 million. Cash and investments totaled USD 0.6 million as of December 31, 2025. On the business side, Artelo reported positive first-in-human Phase 1 single ascending dose data for ART26.12, citing a favorable safety profile and predictable pharmacokinetics, and said it is preparing to open enrollment for a multiple ascending dose study in Q3 2026. The company also announced positive interim Phase 2 CAReS data for ART27.13 in cancer anorexia-cachexia syndrome, and said it received a Notice of Allowance from the European Patent Office covering the intended commercial formulation of ART27.13 with patent protection through December 2041. For ART12.11, Artelo said it received favorable UK MHRA guidance supporting Phase 1 plans and, pending 2026 toxicology results, plans to initiate human studies with an oral solid dosage form in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613711944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613711944","market":"fut","top_or_hot":-1,"title":"Artelo (ARTL) FY 2025 net loss totals USD 12.9 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Artelo (ARTL) FY 2025 net loss totals USD 12.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ARTL\">Artelo Biosciences</a> Inc. reported a FY 2025 net loss of USD 12.9 million, or USD 12.52 per basic and diluted share, alongside R&amp;D expenses of USD 5.4 million and G&amp;A expenses of USD 6.0 million. Cash and investments totaled USD 0.6 million as of December 31, 2025. On the business side, Artelo reported positive first-in-human Phase 1 single ascending dose data for ART26.12, citing a favorable safety profile and predictable pharmacokinetics, and said it is preparing to open enrollment for a multiple ascending dose study in Q3 2026. The company also announced positive interim Phase 2 CAReS data for ART27.13 in cancer anorexia-cachexia syndrome, and said it received a Notice of Allowance from the European Patent Office covering the intended commercial formulation of ART27.13 with patent protection through December 2041. For ART12.11, Artelo said it received favorable UK MHRA guidance supporting Phase 1 plans and, pending 2026 toxicology results, plans to initiate human studies with an oral solid dosage form in H1 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ATLEW\">Artelo Biosciences</a> Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artelo (ARTL) FY 2025 net loss totals USD 12.9 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtelo (ARTL) FY 2025 net loss totals USD 12.9 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Artelo (ARTL) FY 2025 net loss totals USD 12.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ARTL\">Artelo Biosciences</a> Inc. reported a FY 2025 net loss of USD 12.9 million, or USD 12.52 per basic and diluted share, alongside R&amp;D expenses of USD 5.4 million and G&amp;A expenses of USD 6.0 million. Cash and investments totaled USD 0.6 million as of December 31, 2025. On the business side, Artelo reported positive first-in-human Phase 1 single ascending dose data for ART26.12, citing a favorable safety profile and predictable pharmacokinetics, and said it is preparing to open enrollment for a multiple ascending dose study in Q3 2026. The company also announced positive interim Phase 2 CAReS data for ART27.13 in cancer anorexia-cachexia syndrome, and said it received a Notice of Allowance from the European Patent Office covering the intended commercial formulation of ART27.13 with patent protection through December 2041. For ART12.11, Artelo said it received favorable UK MHRA guidance supporting Phase 1 plans and, pending 2026 toxicology results, plans to initiate human studies with an oral solid dosage form in H1 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ATLEW\">Artelo Biosciences</a> Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARTL","symbol_name":"Artelo Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL1lfQ0n:1","article_id":"2613711944","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613711944","pubTimestamp":1771938103,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Artelo Biosciences Inc. reported a FY 2025 net loss of USD 12.9 million, or USD 12.52 per basic and diluted share, alongside R&D expenses of USD 5.4 million and G&A expenses of USD 6.0 million. Cash and investments totaled USD 0.6 million as of December 31, 2025. On the business side, Artelo reported positive first-in-human Phase 1 single ascending dose data for ART26.12, citing a favorable safety profile and predictable pharmacokinetics, and said it is preparing to open enrollment for a multiple ascending dose study in Q3 2026. The company also announced positive interim Phase 2 CAReS data for ART27.13 in cancer anorexia-cachexia syndrome, and said it received a Notice of Allowance from the European Patent Office covering the intended commercial formulation of ART27.13 with patent protection through December 2041. For ART12.11, Artelo said it received favorable UK MHRA guidance supporting Phase 1 plans and, pending 2026 toxicology results, plans to initiate human studies with an oral ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARTL":"Artelo Biosciences, Inc.","BK4007":"制药"},"translate_title":"Artelo(ARTL)2025财年净亏损总额为1290万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTL":0.9},"content_text":"Artelo (ARTL) FY 2025 net loss totals USD 12.9 million\n    \n\nArtelo Biosciences Inc. reported a FY 2025 net loss of USD 12.9 million, or USD 12.52 per basic and diluted share, alongside R&D expenses of USD 5.4 million and G&A expenses of USD 6.0 million. Cash and investments totaled USD 0.6 million as of December 31, 2025. On the business side, Artelo reported positive first-in-human Phase 1 single ascending dose data for ART26.12, citing a favorable safety profile and predictable pharmacokinetics, and said it is preparing to open enrollment for a multiple ascending dose study in Q3 2026. The company also announced positive interim Phase 2 CAReS data for ART27.13 in cancer anorexia-cachexia syndrome, and said it received a Notice of Allowance from the European Patent Office covering the intended commercial formulation of ART27.13 with patent protection through December 2041. For ART12.11, Artelo said it received favorable UK MHRA guidance supporting Phase 1 plans and, pending 2026 toxicology results, plans to initiate human studies with an oral solid dosage form in H1 2027.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613711944","isCrawlerRequest":true}